Cartesian Therapeutics Stock
Cartesian Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Carsten Brunn
- Employees
- 75
- Market cap
- $190 M
- IPO
- 22/06/2016
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen…
Cartesian Therapeutics stock: price history
1D
-4.7%
1W
-11.2%
1M
-20.7%
6M
-10.9%
YTD
-13.0%
1Y
-33.4%
2Y
-71.3%
5Y
-95.1%
10Y
-98.8%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~9% stronger price swings than usual
Ask the agents about Cartesian Therapeutics
Analyst assessment of Cartesian Therapeutics
PRICE TARGET LOW
US$25.00
CONSENSUS
US$25.00
MEDIAN
US$25.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
8
BUY
2
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 30/09/2026
Cartesian Therapeutics stock metrics
P/E
-1.06
P/B
-1.48
EV/EBITDA
-0.67
RETURN ON EQUITY
-11.0%
NET MARGIN
0.0%
DEBT/EQUITY
-0.51
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
38.0%
FLOAT SHARES
11,488,562
AVG. DAILY VOLUME (30D)
140,674
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Cartesian Therapeutics stock
What does Cartesian Therapeutics do?
Cartesian Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Carsten Brunn, the company employs around 75 people.
The IPO was on 22/06/2016; the stock trades on NASDAQ under the ticker RNAC.
What do analysts say about Cartesian Therapeutics stock?
10 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$25.00, ranging from US$25.00 to US$25.00, with a median of US$25.00.
This is an external assessment, not a statement by Market Jury.
When does Cartesian Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 9% stronger than usual.
Does Cartesian Therapeutics pay a dividend?
No, Cartesian Therapeutics currently does not pay a dividend.
Which stocks are comparable to Cartesian Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cartesian Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cartesian Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.